ong-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.
Phase 2
Withdrawn
- Conditions
- Plasma Cell Neoplasm, Lymphomas non-Hodgkin's B-cell, Lymphomas non-Hodgkin's T-cell and LeukaemiasCancer10024324
- Registration Number
- NL-OMON46028
- Lead Sponsor
- Autolus Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
•Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
•Patients must have provided informed consent for long-term follow-up study prior to participation.
•Patients must be able to comply with the study requirements.
Exclusion Criteria
- There are no specific exclusion criteria for this study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method